Reata Pharmaceuticals, Inc. (Nasdaq: RETA) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target an important transcription factor, called Nrf2, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. Read More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Press Releases||View All »|
03/03/17Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2016 Financial and Operating Results
03/02/17Reata Pharmaceuticals, Inc. Announces the Retirement of Board Member Dennis Stone, M.D., and the Addition of New Board Member William D. McClellan, Jr.
|Lee M. Stern, CFA|
The Trout Group
Phone: (646) 378-2922